A sensitive and precise electrothermal atomic absorption spectrophotometric method for determining bismuth concentration is described. Protein precipitation and the use of a palladium modifier reduce the problems of foaming and permit the use of a higher ashing temperature. The detection limit of the assay is 0.9 nmol/L. Total CVs (intraand interassay) for serum ranged from 3.5% to 15.1% and for urine from 4.8% to 14.5% at concentrations of 60.0 and 6.0 nmol/L, respectively. Analytical recoveries of bismuth added to serum and urine were 102% and 103% over the same range. The method is robust and reproducible and can be accurately calibrated with aqueous standards. 
Bismuth
). The acid reservoir was filled with nitric acid, 1.5 mmol/L, and the purge gas was high-purity argon. All glass and plasticware were acid-washed and rinsed three times in de-ionized water (four-bowl Milli-Q system). Aristar Urine. Urine (1.0 mL) was diluted with de-ionized water (5.0 mL) and then treated as in the procedure used for serum.
Standards.
To 500 L of the working standards we added 50 iL of 0.9 mol/L nitric acid and vortex-mixed. The concentration of nitric acid is critical (Figure 1) Furnace conditions. We determined the appropriate furnace settings so that the process proceeded as rapidly as possible through the heating cycle while maintaining full recovery of bismuth (Table 3) . A temperature of 1030 #{176}C was found to be the optimal char temperature for our instrument and 2300#{176}C was used as the atomization temperature. Figure 2A shows the effect of increasing ashing temperature on an unmodified bismuth standard solution. From these results, we concluded that the maximum ashing temperature would be in the range of 250-300 #{176}C. Figure 2B shows the effect of increasing ashing temperature on a palladium-modified bismuth standard solution. The bismuth remained thermally stable up to about 1080 #{176}C, after which a rapid loss of signal was observed. This suggests an improvement in ashing temperature of +700#{176}C with the palladium modifier. The thermal stability of the analyte in the 900-1100 #{176}C region was thoroughly evaluated; the maximum ashing temperature is 1030 #{176}C. Because the actual temperature achieved in the furnace is not measured directly, the maximum thermal pretreatment temperatures must be established for a given instrument.
Results

Method Assessment
We evaluated the method with analytical recovery experiments and serial dilution studies. Serum and no medication) and from patients receiving TDB were used for these experiments. The time to peak appearance observed for bismuth recoveries from pooled normal serum and urine was identical (as judged by overlay tracings) to the time to peak appearance obtained for bismuth in water and in serum from bismuth-medicated patients. Figure 3 shows serial dilution studies of pooled serum and a TDB-medicated patient's serum, respectively. Similarly, Figure 4 shows serial dilution studies of pooled urine and a TDB-medicat.ed patient's urine, respectively. The linearity of these dilution curves is consistent with the conclusion that the method is substantially free of matrix interferences.
A typical response (in argon) for an injection of 20 L of a 70 nmol/L bismuth standard gives about 0.130 A . s. A typical blank measurement was 0.004 A . s and the detection limit (2 SD for determinations of the blank) in our assay is -0.9 nmol/L. Recovery data and reproducibility of the bismuth assay in normal serum and normal urine specimens are presented in Table 4 . Recovery and precision were assessed at four concentrations between 6.0 and 60.0 nmolJL. The mean recoveries and range of recoveries are consistent with complete recovery of added bismuth. The total CV (inter-and intra-assay) ranged from 3.5% at 60 nmol/L to 15.1% at 6 nmolfL.
Reference Interval
To establish a reference range for bismuth in serum, we studied 30 subjects (15 men and 15 women)-healthy laboratory staff, ages 20-56 years, with normal renal function.
To their knowledge they had never taken bismuth medication and none had taken bismuth for 12 months before sample collection. We were unable to detect bismuth in any subject, which suggests that the normal reference value is <0.9 nmol/L. Because the study was originally intended only to monitor bismuth concentrations in patients undergoing treatment with TDB, no further attempt was made to establish a reference range by using preconcentration techniques. 
